{"id":60121,"date":"2026-03-20T12:14:41","date_gmt":"2026-03-20T04:14:41","guid":{"rendered":"https:\/\/flcube.com\/?p=60121"},"modified":"2026-03-20T12:14:42","modified_gmt":"2026-03-20T04:14:42","slug":"luzhu-biotechnology-reports-2025-results-lz901-shingles-vaccine-nears-commercialization-with-shingrix-beating-data","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=60121","title":{"rendered":"Luzhu Biotechnology Reports 2025 Results \u2013 LZ901 Shingles Vaccine Nears Commercialization with Shingrix\u2011Beating Data"},"content":{"rendered":"\n<p><strong>Luzhu Biotechnology<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2480:HKG\">HKG: 2480<\/a>) announced its <strong>audited 2025 annual results<\/strong>, highlighting significant progress toward <strong>LZ901 commercialization<\/strong> in <strong>H2 2026<\/strong> after the recombinant herpes zoster vaccine candidate demonstrated <strong>superior cellular immunogenicity and better safety<\/strong> than <strong>GSK&#8217;s Shingrix\u00ae (HZ\/su)<\/strong> in head\u2011to\u2011head comparison, while narrowing net losses by <strong>10.6%<\/strong> through improved R&amp;D efficiency.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-performance-fy2025\">Financial Performance \u2013 FY2025<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>FY2025<\/th><th>FY2024<\/th><th>Change<\/th><\/tr><\/thead><tbody><tr><td><strong>Other Income<\/strong><\/td><td>RMB 11.0 million<\/td><td>RMB 21.4 million<\/td><td><strong>\u201148.4%<\/strong> (decreased gov&#8217;t grants\/interest)<\/td><\/tr><tr><td><strong>R&amp;D Expenses<\/strong><\/td><td>RMB 96.5 million<\/td><td>RMB 135.1 million<\/td><td><strong>\u201128.6%<\/strong> (LZ901 trial completion, no share\u2011based payment costs)<\/td><\/tr><tr><td><strong>Loss Before Tax<\/strong><\/td><td>RMB 150.4 million<\/td><td>RMB 168.2 million<\/td><td><strong>\u201110.6%<\/strong> (improved efficiency)<\/td><\/tr><tr><td><strong>Cash &amp; Financial Assets<\/strong><\/td><td>RMB 419.4 million<\/td><td>\u2013<\/td><td>Strong liquidity position<\/td><\/tr><tr><td><strong>Unutilized Bank Facilities<\/strong><\/td><td>RMB 400.3 million<\/td><td>\u2013<\/td><td>Additional financing capacity<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Cash Position:<\/strong> Bank balances RMB 95.9 million + financial assets RMB 323.5 million = <strong>total RMB 419.4 million<\/strong><\/li>\n\n\n\n<li><strong>Liquidity Status:<\/strong> &#8220;Relatively ample&#8221; cash reserves with improved overall financial position<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-core-product-lz901-shingles-vaccine\">Core Product \u2013 LZ901 Shingles Vaccine<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Milestone<\/th><th>Status<\/th><th>Timeline<\/th><\/tr><\/thead><tbody><tr><td><strong>BLA Filing<\/strong><\/td><td>Submitted to NMPA<\/td><td>January 2025<\/td><\/tr><tr><td><strong>BLA Acceptance<\/strong><\/td><td>NMPA accepted<\/td><td>February 2025<\/td><\/tr><tr><td><strong>Inspections Complete<\/strong><\/td><td>Clinical + production site<\/td><td>Q3 2025<\/td><\/tr><tr><td><strong>Regulatory Status<\/strong><\/td><td>Under NMPA review<\/td><td>Current<\/td><\/tr><tr><td><strong>Commercialization Target<\/strong><\/td><td>China Mainland launch<\/td><td><strong>H2 2026<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-clinical-evidence\">Clinical Evidence<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Head\u2011to\u2011Head vs. Shingrix\u00ae:<\/strong><\/li>\n\n\n\n<li><strong>Superior cellular immunogenicity<\/strong> in adults \u226550 years<\/li>\n\n\n\n<li><strong>Better safety profile<\/strong> than HZ\/su vaccine<\/li>\n\n\n\n<li><strong>US Phase I:<\/strong> Completed September 2025; high\u2011dose and low\u2011dose groups demonstrated <strong>good safety and immunogenicity<\/strong> vs. placebo \u2013 foundation for subsequent US clinical development<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-pipeline-portfolio-9-candidates\">Pipeline Portfolio \u2013 9 Candidates<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-clinical-stage-3\">Clinical Stage (3)<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Asset<\/th><th>Description<\/th><th>Stage<\/th><th>Next Milestone<\/th><\/tr><\/thead><tbody><tr><td><strong>LZ901<\/strong><\/td><td>Recombinant herpes zoster vaccine (tetrameric structure)<\/td><td>BLA under review<\/td><td>Commercialization H2 2026<\/td><\/tr><tr><td><strong>K3<\/strong><\/td><td>Adalimumab biosimilar (Humira\u00ae) \u2013 autoimmune diseases<\/td><td>Pre\u2011Phase III<\/td><td>Phase III initiation no earlier than 2027<\/td><\/tr><tr><td><strong>K193<\/strong><\/td><td>CD19\/CD3 bispecific antibody \u2013 B\u2011cell leukemia\/lymphoma<\/td><td>Phase I<\/td><td>Completion no earlier than 2027; <strong>world&#8217;s first asymmetric CD19\/CD3 bispecific<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-pre-clinical-stage-6\">Pre\u2011Clinical Stage (6)<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Asset<\/th><th>Target\/Indication<\/th><th>Status Update<\/th><\/tr><\/thead><tbody><tr><td>Recombinant varicella vaccine<\/td><td>VZV prevention<\/td><td>Pre\u2011clinical<\/td><\/tr><tr><td><strong>Recombinant RSV vaccine<\/strong><\/td><td>RSV lower respiratory tract disease<\/td><td><strong>Pre\u2011IND stage (Q4 2025)<\/strong><\/td><\/tr><tr><td>Recombinant HSV\u20111 vaccine<\/td><td>Herpes simplex virus type 1<\/td><td>Pre\u2011IND filing H2 2027<\/td><\/tr><tr><td>Recombinant HSV\u20112 vaccine<\/td><td>Herpes simplex virus type 2<\/td><td>Pre\u2011IND filing H2 2026<\/td><\/tr><tr><td><strong>K333<\/strong><\/td><td>Bispecific antibody \u2013 myeloid leukemia<\/td><td>Pre\u2011clinical<\/td><\/tr><tr><td><strong>K1932<\/strong><\/td><td>Bispecific antibody \u2013 B\u2011cell lymphoma<\/td><td>Pre\u2011clinical<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-operational-infrastructure\">Operational Infrastructure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Facility<\/th><th>Location<\/th><th>Status<\/th><\/tr><\/thead><tbody><tr><td><strong>R&amp;D Facility<\/strong><\/td><td>Yizhuang, Beijing<\/td><td><strong>Operational since August 2025<\/strong><\/td><\/tr><tr><td><strong>Manufacturing Facility<\/strong><\/td><td>Beijing<\/td><td>Trial operation <strong>H2 2026<\/strong><\/td><\/tr><tr><td><strong>Manufacturing Team<\/strong><\/td><td>\u2013<\/td><td><strong>48 personnel<\/strong> (as of Dec 2025)<\/td><\/tr><tr><td><strong>Commercial Team<\/strong><\/td><td>\u2013<\/td><td><strong>11 personnel<\/strong> (established H2 2025)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-outlook\">Strategic Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>LZ901 Commercialization Priority:<\/strong> NMPA approval expected H1 2026 with H2 2026 China launch; manufacturing readiness and 11\u2011person commercial team scale\u2011up critical for market entry against established Shingrix\u00ae franchise.<\/li>\n\n\n\n<li><strong>Pipeline Diversification:<\/strong> RSV vaccine (pre\u2011IND) and HSV vaccines (2026\u20112027) expand infectious disease portfolio; K333\/K1932 bispecifics leverage asymmetric antibody platform validated by K193.<\/li>\n\n\n\n<li><strong>R&amp;D Efficiency Focus:<\/strong> 28.6% R&amp;D cost reduction demonstrates disciplined capital allocation post\u2011LZ901 pivotal trials; future investment weighted toward pre\u2011clinical advancement and US clinical expansion.<\/li>\n\n\n\n<li><strong>Funding Runway:<\/strong> RMB 419 million cash + RMB 400 million unutilized facilities provides <strong>2.5\u20113 years<\/strong> operational runway at current burn rate; potential IPO follow\u2011on or partnership financing ahead of K3 Phase III initiation.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding LZ901 approval timelines, commercialization expectations, and pipeline development milestones. Actual results may differ due to regulatory delays, competitive dynamics, and manufacturing scale\u2011up challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Luzhu Biotechnology (HKG: 2480) announced its audited 2025 annual results, highlighting significant progress toward LZ901&#8230;<\/p>\n","protected":false},"author":1,"featured_media":60122,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[1],"tags":[184,1640,1641],"class_list":["post-60121","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized","tag-gsk","tag-hkg-2480","tag-luzhu-biotechnology"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Luzhu Biotechnology Reports 2025 Results \u2013 LZ901 Shingles Vaccine Nears Commercialization with Shingrix\u2011Beating Data - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Luzhu Biotechnology (HKG: 2480) announced its audited 2025 annual results, highlighting significant progress toward LZ901 commercialization in H2 2026 after the recombinant herpes zoster vaccine candidate demonstrated superior cellular immunogenicity and better safety than GSK&#039;s Shingrix\u00ae (HZ\/su) in head\u2011to\u2011head comparison, while narrowing net losses by 10.6% through improved R&amp;D efficiency.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=60121\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Luzhu Biotechnology Reports 2025 Results \u2013 LZ901 Shingles Vaccine Nears Commercialization with Shingrix\u2011Beating Data\" \/>\n<meta property=\"og:description\" content=\"Luzhu Biotechnology (HKG: 2480) announced its audited 2025 annual results, highlighting significant progress toward LZ901 commercialization in H2 2026 after the recombinant herpes zoster vaccine candidate demonstrated superior cellular immunogenicity and better safety than GSK&#039;s Shingrix\u00ae (HZ\/su) in head\u2011to\u2011head comparison, while narrowing net losses by 10.6% through improved R&amp;D efficiency.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=60121\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-20T04:14:41+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-20T04:14:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2001.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60121#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60121\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Luzhu Biotechnology Reports 2025 Results \u2013 LZ901 Shingles Vaccine Nears Commercialization with Shingrix\u2011Beating Data\",\"datePublished\":\"2026-03-20T04:14:41+00:00\",\"dateModified\":\"2026-03-20T04:14:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60121\"},\"wordCount\":533,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60121#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/2001.webp\",\"keywords\":[\"GSK\",\"HKG: 2480\",\"Luzhu Biotechnology\"],\"articleSection\":[\"Others\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=60121#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60121\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=60121\",\"name\":\"Luzhu Biotechnology Reports 2025 Results \u2013 LZ901 Shingles Vaccine Nears Commercialization with Shingrix\u2011Beating Data - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60121#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60121#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/2001.webp\",\"datePublished\":\"2026-03-20T04:14:41+00:00\",\"dateModified\":\"2026-03-20T04:14:42+00:00\",\"description\":\"Luzhu Biotechnology (HKG: 2480) announced its audited 2025 annual results, highlighting significant progress toward LZ901 commercialization in H2 2026 after the recombinant herpes zoster vaccine candidate demonstrated superior cellular immunogenicity and better safety than GSK's Shingrix\u00ae (HZ\\\/su) in head\u2011to\u2011head comparison, while narrowing net losses by 10.6% through improved R&D efficiency.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60121#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=60121\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60121#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/2001.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/2001.webp\",\"width\":1080,\"height\":608,\"caption\":\"Luzhu Biotechnology Reports 2025 Results \u2013 LZ901 Shingles Vaccine Nears Commercialization with Shingrix\u2011Beating Data\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60121#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Luzhu Biotechnology Reports 2025 Results \u2013 LZ901 Shingles Vaccine Nears Commercialization with Shingrix\u2011Beating Data\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Luzhu Biotechnology Reports 2025 Results \u2013 LZ901 Shingles Vaccine Nears Commercialization with Shingrix\u2011Beating Data - Insight, China&#039;s Pharmaceutical Industry","description":"Luzhu Biotechnology (HKG: 2480) announced its audited 2025 annual results, highlighting significant progress toward LZ901 commercialization in H2 2026 after the recombinant herpes zoster vaccine candidate demonstrated superior cellular immunogenicity and better safety than GSK's Shingrix\u00ae (HZ\/su) in head\u2011to\u2011head comparison, while narrowing net losses by 10.6% through improved R&D efficiency.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=60121","og_locale":"en_US","og_type":"article","og_title":"Luzhu Biotechnology Reports 2025 Results \u2013 LZ901 Shingles Vaccine Nears Commercialization with Shingrix\u2011Beating Data","og_description":"Luzhu Biotechnology (HKG: 2480) announced its audited 2025 annual results, highlighting significant progress toward LZ901 commercialization in H2 2026 after the recombinant herpes zoster vaccine candidate demonstrated superior cellular immunogenicity and better safety than GSK's Shingrix\u00ae (HZ\/su) in head\u2011to\u2011head comparison, while narrowing net losses by 10.6% through improved R&D efficiency.","og_url":"https:\/\/flcube.com\/?p=60121","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-20T04:14:41+00:00","article_modified_time":"2026-03-20T04:14:42+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2001.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=60121#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=60121"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Luzhu Biotechnology Reports 2025 Results \u2013 LZ901 Shingles Vaccine Nears Commercialization with Shingrix\u2011Beating Data","datePublished":"2026-03-20T04:14:41+00:00","dateModified":"2026-03-20T04:14:42+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=60121"},"wordCount":533,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=60121#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2001.webp","keywords":["GSK","HKG: 2480","Luzhu Biotechnology"],"articleSection":["Others"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=60121#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=60121","url":"https:\/\/flcube.com\/?p=60121","name":"Luzhu Biotechnology Reports 2025 Results \u2013 LZ901 Shingles Vaccine Nears Commercialization with Shingrix\u2011Beating Data - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=60121#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=60121#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2001.webp","datePublished":"2026-03-20T04:14:41+00:00","dateModified":"2026-03-20T04:14:42+00:00","description":"Luzhu Biotechnology (HKG: 2480) announced its audited 2025 annual results, highlighting significant progress toward LZ901 commercialization in H2 2026 after the recombinant herpes zoster vaccine candidate demonstrated superior cellular immunogenicity and better safety than GSK's Shingrix\u00ae (HZ\/su) in head\u2011to\u2011head comparison, while narrowing net losses by 10.6% through improved R&D efficiency.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=60121#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=60121"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=60121#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2001.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2001.webp","width":1080,"height":608,"caption":"Luzhu Biotechnology Reports 2025 Results \u2013 LZ901 Shingles Vaccine Nears Commercialization with Shingrix\u2011Beating Data"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=60121#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Luzhu Biotechnology Reports 2025 Results \u2013 LZ901 Shingles Vaccine Nears Commercialization with Shingrix\u2011Beating Data"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2001.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/60121","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=60121"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/60121\/revisions"}],"predecessor-version":[{"id":60123,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/60121\/revisions\/60123"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/60122"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=60121"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=60121"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=60121"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}